Status:
COMPLETED
Prognostic Value of Her2neu and EGFR in Primary Ovarian High Grade Serous Carcinoma.
Lead Sponsor:
Port Said University hospital
Conditions:
Ovarian Cancer
Eligibility:
FEMALE
Brief Summary
To assess alterations of EGFR\& Her2neu expression in primary ovarian high grade serous carcinoma and its correlation with other clinicopathological parameters
Detailed Description
Ovarian cancer (OC) is the seventh most common cancer and the fifth cause of cancer death in women worldwide. The most frequent type is surface epithelial tumors. It is frequently diagnosed at advance...
Eligibility Criteria
Inclusion
- Patients with primary ovarian cancer
Exclusion
- patients with secondary ovarian cancer
Key Trial Info
Start Date :
January 1 2012
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 30 2019
Estimated Enrollment :
54 Patients enrolled
Trial Details
Trial ID
NCT04284631
Start Date
January 1 2012
End Date
December 30 2019
Last Update
April 1 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.